Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many interaction and skeletal muscle risk claims align with label language (notably CYP3A4 inhibitors, clarithromycin/itraconazole, cyclosporine dosing limit, grapefruit consumption thresholds, and advice to report unexplained muscle pain). However, several claims are not supported by the provided label excerpts (e.g., dark/tea-colored urine; warfarin INR monitoring; DOAC unpredictability; glucose effects/management; general prescriber response patterns). There are also mechanism/specificity overreaches (HIV/HCV antiviral transporter mechanism; ketoconazole naming; gemfibrozil naming).
Category Scores
Accurate Statements
Atorvastatin has clinically important interactions, especially when other drugs raise its concentration or increase muscle-risk.
7 DRUG INTERACTIONS; 5.1 Skeletal Muscle
Strong CYP3A4 inhibitors can raise atorvastatin levels and increase side-effect risk, including muscle problems.
7.1 Strong Inhibitors of CYP 3A4; 5.1 Skeletal Muscle; 7 DRUG INTERACTIONS
Macrolide antibiotics (such as clarithromycin) can increase atorvastatin exposure via CYP3A4 inhibition.
7.1 Strong Inhibitors of CYP 3A4 (clarithromycin AUC increased); 5.1 Skeletal Muscle
Azole antifungals (such as itraconazole) can increase atorvastatin exposure via CYP3A4 inhibition.
7.1 Strong Inhibitors of CYP 3A4 (itraconazole AUC increased); 5.1 Skeletal Muscle
Grapefruit juice can increase atorvastatin levels by affecting CYP3A4 in the gut.
7.2 Grapefruit Juice
The risk of statin-associated muscle problems/myopathy including rhabdomyolysis is increased with certain drug combinations and interacting agents.
5.1 Skeletal Muscle; 6 ADVERSE REACTIONS
Patients should report promptly unexplained muscle pain, tenderness, or weakness (and risk is increased with grapefruit consumption and certain medications).
5.1 Skeletal Muscle; 17.1 Muscle Pain
Unsupported Statements
Patients taking atorvastatin should seek urgent care if they develop dark or tea-colored urine.
Not supported by the provided label excerpts (no mention in 5.1/17.1/7 excerpts).
Some drug interactions that increase atorvastatin exposure may cause the same muscle-symptom outcomes even at lower doses when interacting medications are present.
No explicit label statement in the provided excerpts.
Atorvastatin can affect anticoagulant control in some situations.
Not supported by the provided excerpts (warfarin section indicates no clinically significant effect on prothrombin time; no broader anticoagulant control claim supported here).
If taking warfarin, clinicians often recommend closer INR monitoring after starting atorvastatin, changing the dose, or starting/stopping other interacting drugs.
Not supported by the provided label excerpt for warfarin (7.7 states no clinically significant effect on prothrombin time); no INR monitoring recommendation provided.
For direct oral anticoagulants, interactions with atorvastatin are less predictable and depend on the specific agent and other co-medications.
Not supported by the provided label excerpts.
Atorvastatin can slightly increase blood glucose in some patients.
Not supported by the provided label excerpts.
Atorvastatin can change how glucose control looks overall when combined with diabetes medicines.
Not supported by the provided label excerpts.
Management of atorvastatin combined with diabetes medicines is usually by monitoring and adjusting the diabetes regimen rather than avoiding the combination.
Not supported by the provided label excerpts.
Clinicians typically respond to interaction risk with atorvastatin by avoiding the interacting drug when possible.
No explicit 'avoid when possible' prescriber-behavior statement in provided excerpts.
Clinicians typically respond to interaction risk with atorvastatin by using an alternative that does not raise atorvastatin exposure as much.
Not supported by provided label excerpts.
Clinicians typically respond ... by lowering the atorvastatin dose.
Only condition-specific dose-limit/caution statements are present (e.g., cyclosporine dose not to exceed 10 mg; caution when exceeding >20 mg with certain CYP3A4 inhibitors). The general 'typically' framing is not explicitly supported.
Contradictions
Important Omissions
Specific 'prescribing recommendations' tied to interacting agents (e.g., dose limits such as 'do not exceed 10 mg' with cyclosporine; caution when exceeding >20 mg with clarithromycin/itraconazole/HIV protease inhibitors) are not clearly reflected as explicit dose recommendations throughout the extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Most skeletal muscle reporting guidance in the excerpts is consistent with labeling; however, the inclusion of 'dark/tea-colored urine' as an urgent-care symptom is not supported by the provided label text and could mislead triage. Several other safety-relevant interaction-management claims are unsupported or overgeneralized (e.g., INR monitoring guidance), which reduces label fidelity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple extracted claims are not supported by the provided FDA label excerpts, including a potentially safety-relevant symptom (dark/tea-colored urine) and several medication-management assertions (warfarin INR monitoring, DOAC predictability, glucose effects). Mechanism and specificity examples (HCV transporter effects; ketoconazole; gemfibrozil) are also not fully supported.
Suggested Improvement
Remove or re-qualify unsupported symptom and monitoring/management claims; align dosing/interaction guidance to explicit label recommendations (e.g., cyclosporine dose limit; caution thresholds >20 mg with specific CYP3A4 inhibitors). Restrict examples to agents explicitly named in the provided label sections (e.g., itraconazole but not ketoconazole; fibric acid derivatives without unsupported gemfibrozil specificity).